Show simple item record

dc.contributor.authorMohn, Kristin Greve-Isdahl
dc.contributor.authorBrokstad, Karl Albert
dc.contributor.authorIslam, Shahinul
dc.contributor.authorOftung, Fredrik
dc.contributor.authorTøndel, Camilla
dc.contributor.authorAarstad, Hans Jørgen
dc.contributor.authorCox, Rebecca Jane
dc.description.abstractBackground Live-attenuated influenza vaccine (LAIV) was licensed for prophylaxis of children 2–17 years old in Europe in 2012 and is administered as a nasal spray. Live-attenuated influenza vaccine induces both mucosal and systemic antibodies and systemic T-cell responses. Tonsils are the lymph nodes serving the upper respiratory tract, acting as both induction and effector site for mucosal immunity. Methods Here, we have studied the early tonsillar T-cell responses induced in children after LAIV. Thirty-nine children were immunized with trivalent LAIV (containing A/H1N1, A/H3N2, and B viruses) at days 3, 7, and 14 before tonsillectomy. Nonvaccinated controls were included for comparison. Tonsils and peripheral blood (pre- and postvaccination) were collected to study T-cell responses. Results Tonsillar and systemic T-cell responses differed between influenza strains, and both were found against H3N2 and B viruses, whereas only systemic responses were observed against A/H1N1. A significant increase in cross-reactive tonsillar CD8+ T cells recognizing conserved epitopes from a broad range of seasonal and pandemic viruses occurred at day 14. Tonsillar T cells showed significant cytokine responses (Th1, Th2, and granulocyte-macrophage colony-stimulating factor). Conclusions Our findings support the use of LAIV in children to elicit broadly cross-reactive T cells, which are not induced by traditional inactivated influenza vaccines and may provide protection to novel virus strains.en_US
dc.publisherOxford University Pressen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleEarly Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Childrenen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2019 The Authorsen_US
dc.source.journalJournal of Infectious Diseasesen_US
dc.relation.projectNorges forskningsråd: 271160en_US
dc.relation.projectNorges forskningsråd: 284930en_US
dc.relation.projectNorges forskningsråd: 811752en_US
dc.relation.projectNorges forskningsråd: 815818en_US
dc.identifier.citationJournal of Infectious Diseases. 2020, 221(9), 1528–1537en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal